Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.46 |
| ▸ | POLA1 | P09884 | 2/20 | 0.46 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6668136 | 0.88 | KCNH2 (0.50) | KCNH2POLA1MLLT1ALDH1A1NPC1 | |
| SCHEMBL6667336 | 0.88 | KCNH2 (0.48) | KCNH2POLA1MLLT1ALDH1A1NPC1 | |
| SCHEMBL6667277 | 0.87 | KCNH2 (0.49) | KCNH2POLA1MLLT1ALDH1A1NPC1 | |
| SCHEMBL6667809 | 0.86 | KCNH2 (0.45) | KCNH2POLA1MLLT1ALDH1A1NPC1 | |
| SCHEMBL6668123 | 0.86 | KCNH2 (0.49) | KCNH2POLA1MLLT1ALDH1A1NPC1 | |
| SCHEMBL6669978 | 0.85 | MAPK1 (0.38) | KCNH2ALDH1A1MAPT | |
| SCHEMBL6669311 | 0.84 | KCNH2 (0.48) | KCNH2POLA1MLLT1ALDH1A1NPC1 | |
| SCHEMBL6668378 | 0.84 | POLA1 (0.47) | KCNH2POLA1MLLT1ALDH1A1NPC1 | |
| SCHEMBL6669343 | 0.84 | POLA1 (0.47) | KCNH2POLA1MLLT1ALDH1A1NPC1 | |
| SCHEMBL6667914 | 0.84 | POLA1 (0.47) | KCNH2POLA1MLLT1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004019940-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |
| EP-1265872-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001081318-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-01 | — | — | WO | claimed |
| WO-2004019940-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1265872-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001081318-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |